US4270537A
(en)
|
1979-11-19 |
1981-06-02 |
Romaine Richard A |
Automatic hypodermic syringe
|
US4996335A
(en)
|
1980-07-10 |
1991-02-26 |
Nicholas S. Bodor |
Soft steroids having anti-inflammatory activity
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
US4789724A
(en)
|
1986-10-17 |
1988-12-06 |
Massachusetts Institute Of Technology |
Preparation of anhydride copolymers
|
CA1283827C
(en)
|
1986-12-18 |
1991-05-07 |
Giorgio Cirelli |
Appliance for injection of liquid formulations
|
GB8704027D0
(en)
|
1987-02-20 |
1987-03-25 |
Owen Mumford Ltd |
Syringe needle combination
|
US4940460A
(en)
|
1987-06-19 |
1990-07-10 |
Bioject, Inc. |
Patient-fillable and non-invasive hypodermic injection device assembly
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
CA1325382C
(en)
|
1988-01-27 |
1993-12-21 |
Takahiro Ogawa |
Locally administrable therapeutic composition for inflammatory disease
|
US5339163A
(en)
|
1988-03-16 |
1994-08-16 |
Canon Kabushiki Kaisha |
Automatic exposure control device using plural image plane detection areas
|
FR2638359A1
(fr)
|
1988-11-03 |
1990-05-04 |
Tino Dalto |
Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
|
US5442039A
(en)
|
1989-07-17 |
1995-08-15 |
The Dow Chemical Company |
Mesogenic polycyanates and thermosets thereof
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
US5190521A
(en)
|
1990-08-22 |
1993-03-02 |
Tecnol Medical Products, Inc. |
Apparatus and method for raising a skin wheal and anesthetizing skin
|
US5190956A
(en)
|
1990-09-07 |
1993-03-02 |
Schering Corporation |
Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections
|
US5527288A
(en)
|
1990-12-13 |
1996-06-18 |
Elan Medical Technologies Limited |
Intradermal drug delivery device and method for intradermal delivery of drugs
|
EP0597956A1
(en)
|
1991-07-29 |
1994-05-25 |
Warner-Lambert Company |
Quinazoline derivatives as acetylcholinesterase inhibitors
|
GB9118204D0
(en)
|
1991-08-23 |
1991-10-09 |
Weston Terence E |
Needle-less injector
|
SE9102652D0
(sv)
|
1991-09-13 |
1991-09-13 |
Kabi Pharmacia Ab |
Injection needle arrangement
|
US5328483A
(en)
|
1992-02-27 |
1994-07-12 |
Jacoby Richard M |
Intradermal injection device with medication and needle guard
|
US6235313B1
(en)
|
1992-04-24 |
2001-05-22 |
Brown University Research Foundation |
Bioadhesive microspheres and their use as drug delivery and imaging systems
|
US6197346B1
(en)
|
1992-04-24 |
2001-03-06 |
Brown Universtiy Research Foundation |
Bioadhesive microspheres and their use as drug delivery and imaging systems
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
US5569189A
(en)
|
1992-09-28 |
1996-10-29 |
Equidyne Systems, Inc. |
hypodermic jet injector
|
US5334144A
(en)
|
1992-10-30 |
1994-08-02 |
Becton, Dickinson And Company |
Single use disposable needleless injector
|
AU660852B2
(en)
|
1992-11-25 |
1995-07-06 |
Elan Pharma International Limited |
Method of grinding pharmaceutical substances
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
US5364884A
(en)
|
1993-01-21 |
1994-11-15 |
Baylor College Of Medicine |
Arginine compounds as ocular hypotensive agents
|
US5534259A
(en)
|
1993-07-08 |
1996-07-09 |
Liposome Technology, Inc. |
Polymer compound and coated particle composition
|
CA2167920A1
(en)
|
1993-07-23 |
1995-02-02 |
Abraham J. Domb |
Nonoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
|
US5540930A
(en)
|
1993-10-25 |
1996-07-30 |
Pharmos Corporation |
Suspension of loteprednol etabonate for ear, eye, or nose treatment
|
DE69505949T2
(de)
|
1994-02-17 |
1999-06-02 |
Pankaj Hamilton Ontario Modi |
Arzneimittel, impfstoffe und hormone in polylaktidbeschichteten mikropartikel
|
WO1995024176A1
(en)
|
1994-03-07 |
1995-09-14 |
Bioject, Inc. |
Ampule filling device
|
AU2096895A
(en)
|
1994-03-07 |
1995-09-25 |
Sugen, Incorporated |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
US5466220A
(en)
|
1994-03-08 |
1995-11-14 |
Bioject, Inc. |
Drug vial mixing and transfer device
|
GB9406094D0
(en)
|
1994-03-28 |
1994-05-18 |
Univ Nottingham And University |
Polymer microspheres and a method of production thereof
|
US5718388A
(en)
|
1994-05-25 |
1998-02-17 |
Eastman Kodak |
Continuous method of grinding pharmaceutical substances
|
TW384224B
(en)
|
1994-05-25 |
2000-03-11 |
Nano Sys Llc |
Method of preparing submicron particles of a therapeutic or diagnostic agent
|
US5599302A
(en)
|
1995-01-09 |
1997-02-04 |
Medi-Ject Corporation |
Medical injection system and method, gas spring thereof and launching device using gas spring
|
US5730723A
(en)
|
1995-10-10 |
1998-03-24 |
Visionary Medical Products Corporation, Inc. |
Gas pressured needle-less injection device and method
|
GB9514265D0
(en)
|
1995-07-13 |
1995-09-13 |
Wellcome Found |
Hetrocyclic compounds
|
WO1997020578A1
(en)
|
1995-12-04 |
1997-06-12 |
University Of Miami |
Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
|
US6046208A
(en)
|
1996-01-11 |
2000-04-04 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
US5893397A
(en)
|
1996-01-12 |
1999-04-13 |
Bioject Inc. |
Medication vial/syringe liquid-transfer apparatus
|
GB9607549D0
(en)
|
1996-04-11 |
1996-06-12 |
Weston Medical Ltd |
Spring-powered dispensing device
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
US6106819A
(en)
|
1996-12-31 |
2000-08-22 |
Sucher; David F. |
Methods of treating headache and functional extraocular and intraocular myotendinitis
|
ZA9711732B
(en)
|
1996-12-31 |
1998-12-28 |
Quadrant Holdings Cambridge |
Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
|
AU744089C
(en)
|
1997-01-06 |
2003-07-31 |
Cerus Corporation |
Frangible compounds for pathogen inactivation
|
PT954282E
(pt)
|
1997-01-16 |
2005-06-30 |
Massachusetts Inst Technology |
Preparacao de particulas para inalacao
|
US5993412A
(en)
|
1997-05-19 |
1999-11-30 |
Bioject, Inc. |
Injection apparatus
|
US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
GB9713980D0
(en)
|
1997-07-03 |
1997-09-10 |
Danbiosyst Uk |
New conjugates
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
FR2772763B1
(fr)
|
1997-12-24 |
2004-01-23 |
Sod Conseils Rech Applic |
Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
|
IT1298087B1
(it)
|
1998-01-08 |
1999-12-20 |
Fiderm S R L |
Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
US6165509A
(en)
|
1998-09-01 |
2000-12-26 |
University Of Washington |
Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
|
CA2344169C
(en)
|
1998-09-29 |
2011-07-19 |
American Cyanamid Company |
Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
PT1119567E
(pt)
|
1998-10-08 |
2005-08-31 |
Astrazeneca Ab |
Derivados de quinazolina
|
US6372246B1
(en)
|
1998-12-16 |
2002-04-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
|
IL143962A0
(en)
|
1999-01-08 |
2002-04-21 |
Emisphere Tech Inc |
Polymeric delivery agents and delivery agent compounds
|
GB2345486A
(en)
|
1999-01-11 |
2000-07-12 |
Glaxo Group Ltd |
Heteroaromatic protein tyrosine kinase inhibitors
|
JP2002534512A
(ja)
|
1999-01-15 |
2002-10-15 |
ノボ ノルディスク アクティーゼルスカブ |
非ペプチドglp−1アゴニスト
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
MXPA01007895A
(es)
|
1999-02-03 |
2003-07-21 |
Biosante Pharmaceuticals Inc |
Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos.
|
CZ303692B6
(cs)
*
|
1999-02-10 |
2013-03-13 |
Astrazeneca Ab |
Chinazolinové deriváty jako inhibitory angiogeneze
|
EE200100449A
(et)
|
1999-02-27 |
2002-12-16 |
Boehringer Ingelheim Pharma Kg |
4-aminokinasoliini ja kinoliini derivaadid inhibeeriva toimega türosiinkinaaside vahendatud signaali ülekandele
|
DE19911509A1
(de)
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6972296B2
(en)
|
1999-05-07 |
2005-12-06 |
Encysive Pharmaceuticals Inc. |
Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
US6264981B1
(en)
|
1999-10-27 |
2001-07-24 |
Anesta Corporation |
Oral transmucosal drug dosage using solid solution
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
AR035851A1
(es)
|
2000-03-28 |
2004-07-21 |
Wyeth Corp |
3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
|
CA2404665A1
(en)
|
2000-03-30 |
2001-10-11 |
The Penn State Research Foundation |
Novel compounds for enhancing chemotherapy
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
AU2001276536B2
(en)
|
2000-08-09 |
2007-01-04 |
Astrazeneca Ab |
Quinoline derivatives having vegf inhibiting activity
|
DE10042059A1
(de)
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
EP1650203B1
(en)
|
2000-09-11 |
2008-02-20 |
Novartis Vaccines and Diagnostics, Inc. |
Process of preparation of benzimidazol-2-yl quinolinone derivatives
|
FR2814167B1
(fr)
|
2000-09-15 |
2002-11-08 |
Aventis Pharma Sa |
Preparation de la camptothecine et de ses derives
|
CA2426684A1
(en)
|
2000-10-25 |
2002-08-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
AU2000202A
(en)
|
2000-10-31 |
2002-05-15 |
Pr Pharmaceuticals Inc |
Methods and compositions for enhanced delivery of bioactive molecules
|
GB0027357D0
(en)
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
GB2370839A
(en)
|
2001-01-06 |
2002-07-10 |
Benedikt Timmerman |
Immunogenic complex useful for disease control
|
US6855720B2
(en)
|
2001-03-01 |
2005-02-15 |
California Pacific Medical Center |
Nitrogen-based camptothecin derivatives
|
ATE325795T1
(de)
|
2001-03-23 |
2006-06-15 |
Bayer Corp |
Rho-kinase inhibitoren
|
WO2002088079A2
(en)
|
2001-05-01 |
2002-11-07 |
Bristol-Myers Squibb Company |
Dual inhibitors of pde 7 and pde 4
|
SE0101675D0
(sv)
|
2001-05-11 |
2001-05-11 |
Astrazeneca Ab |
Novel composition
|
DE10128110A1
(de)
|
2001-06-11 |
2003-01-02 |
Univ Hannover |
Verbindungen zum Anlagern an Nucleinsäuren
|
PE20030008A1
(es)
|
2001-06-19 |
2003-01-22 |
Bristol Myers Squibb Co |
Inhibidores duales de pde 7 y pde 4
|
EP1408980A4
(en)
|
2001-06-21 |
2004-10-20 |
Ariad Pharma Inc |
NEW QUINAZOLINES AND THEIR USE
|
US6713462B2
(en)
|
2001-06-21 |
2004-03-30 |
Ariad Pharmaceuticals, Inc. |
Quinolinones and uses thereof
|
DE60237449D1
(de)
|
2001-06-22 |
2010-10-07 |
Univ Johns Hopkins Med |
Ammensetzungen und damit in beziehung stehende verwendungen
|
US20050191359A1
(en)
|
2001-09-28 |
2005-09-01 |
Solubest Ltd. |
Water soluble nanoparticles and method for their production
|
GB0126433D0
(en)
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
GB0128108D0
(en)
|
2001-11-23 |
2002-01-16 |
Astrazeneca Ab |
Therapeutic use
|
US7084156B2
(en)
|
2001-11-27 |
2006-08-01 |
Merck & Co., Inc. |
2-Aminoquinoline compounds
|
CA2468159A1
(en)
|
2001-11-27 |
2003-06-05 |
Merck & Co., Inc. |
4-aminoquinoline compounds
|
AU2002365611A1
(en)
|
2001-12-05 |
2003-06-17 |
F. Hoffmann - La Roche Ag |
Inflammation modulators
|
WO2003053926A1
(fr)
|
2001-12-13 |
2003-07-03 |
Ajinomoto Co.,Inc. |
Nouveau derive de phenylalanine
|
WO2003051906A2
(en)
|
2001-12-14 |
2003-06-26 |
Smithkline Beecham Corporation |
Compounds and methods
|
CN101607958A
(zh)
|
2002-02-01 |
2009-12-23 |
阿斯特拉曾尼卡有限公司 |
喹唑啉化合物
|
US6822097B1
(en)
|
2002-02-07 |
2004-11-23 |
Amgen, Inc. |
Compounds and methods of uses
|
AU2006220411B2
(en)
|
2002-03-20 |
2008-06-26 |
Alkermes, Inc. |
Inhalable Sustained Therapeutic Formulations
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
JPWO2003101491A1
(ja)
|
2002-06-03 |
2005-09-29 |
三菱ウェルファーマ株式会社 |
Her2又は/及びEGFR発現又は活性化対象に用いる予防又は/及び治療剤
|
AU2003288899B2
(en)
|
2002-08-23 |
2009-09-03 |
Novartis Vaccines And Diagnostics, Inc. |
Benzimidazole quinolinones and uses thereof
|
US20050256157A1
(en)
|
2002-08-23 |
2005-11-17 |
Chiron Corporation |
Combination therapy with CHK1 inhibitors
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
CA2500218A1
(en)
|
2002-09-26 |
2004-04-08 |
Yamanouchi Pharmaceutical Co., Ltd. |
Drug absorptivity improving agent
|
JP2006521280A
(ja)
|
2002-11-08 |
2006-09-21 |
シェーリング コーポレイション |
インテグリンがそのレセプターに結合するのを阻害するカルボン酸誘導体と他の治療化合物とを含む、組み合わせ生成物
|
US7488823B2
(en)
|
2003-11-10 |
2009-02-10 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
WO2004046101A2
(en)
|
2002-11-20 |
2004-06-03 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
|
DE60324461D1
(de)
|
2002-12-24 |
2008-12-11 |
Astrazeneca Ab |
Therapeutische quinazolin-derivate
|
CN1753889A
(zh)
|
2002-12-24 |
2006-03-29 |
阿斯利康(瑞典)有限公司 |
喹唑啉化合物
|
PL223998B1
(pl)
|
2002-12-24 |
2016-11-30 |
Astrazeneca Ab |
N-(3-Fluorofenylo)-2-{3-[(7-{3-[etylo(2-hydroksyetylo)amino]propoksy}chinazolin-4-ylo)amino]-1H-pirazol-5-ilo} acetamid oraz jego kompozycja farmaceutyczna
|
WO2004060400A1
(ja)
|
2003-01-06 |
2004-07-22 |
Mitsubishi Pharma Corp |
上皮成長因子受容体を分子標的とする抗精神病薬
|
US20050266090A1
(en)
|
2003-04-29 |
2005-12-01 |
Ales Prokop |
Nanoparticular targeting and therapy
|
US20050058603A1
(en)
|
2003-05-02 |
2005-03-17 |
Case Western Reserve University |
Drug delivery system based on polymer nanoshells
|
US7842232B2
(en)
|
2003-05-22 |
2010-11-30 |
Elan Pharma International, Ltd. |
Sterilization of dispersions of nanoparticulate active agents with gamma radiation
|
US7727969B2
(en)
|
2003-06-06 |
2010-06-01 |
Massachusetts Institute Of Technology |
Controlled release nanoparticle having bound oligonucleotide for targeted delivery
|
DE10331500A1
(de)
|
2003-07-11 |
2005-02-24 |
Zentaris Gmbh |
Neue Acridin-Derivate und deren Verwendung als Arzneimittel
|
US20050009809A1
(en)
|
2003-07-11 |
2005-01-13 |
Matthias Gerlach |
Acridine derivatives and their use as medicaments
|
US20050124562A1
(en)
|
2003-09-23 |
2005-06-09 |
Joseph Guiles |
Bis-quinazoline compounds for the treatment of bacterial infections
|
WO2005035521A1
(en)
|
2003-10-09 |
2005-04-21 |
Argenta Discovery Ltd. |
Substituted quinolines as mcr modulators
|
US20050137399A1
(en)
|
2003-11-07 |
2005-06-23 |
Chiron Corporation |
Methods for synthesizing quinolinone compounds
|
GB0330002D0
(en)
*
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
CA2553423C
(en)
|
2004-01-23 |
2012-03-20 |
Amgen Inc. |
Heterocyclic compounds for use in the treatment of cancer and the inhibition of angiogenesis
|
US7626030B2
(en)
|
2004-01-23 |
2009-12-01 |
Amgen Inc. |
Compounds and methods of use
|
WO2005072710A2
(en)
|
2004-01-28 |
2005-08-11 |
Johns Hopkins University |
Drugs and gene carrier particles that rapidly move through mucous barriers
|
SE0400284D0
(sv)
|
2004-02-10 |
2004-02-10 |
Astrazeneca Ab |
Novel compounds
|
TW200529846A
(en)
|
2004-02-20 |
2005-09-16 |
Wyeth Corp |
3-quinolinecarbonitrile protein kinase inhibitors
|
US7875624B2
(en)
|
2004-02-20 |
2011-01-25 |
Novartis Vaccines And Diagnostics, Inc. |
Modulating and measuring cellular adhesion
|
US20050266067A1
(en)
|
2004-03-02 |
2005-12-01 |
Shiladitya Sengupta |
Nanocell drug delivery system
|
ATE441419T1
(de)
|
2004-03-25 |
2009-09-15 |
Bausch & Lomb |
Verwendung von loteprednoletabonat zur behanldung von trockenen augen
|
WO2005097137A2
(en)
|
2004-03-31 |
2005-10-20 |
The Scripps Research Institute |
Advanced quinazoline based protein kinase inhibitors
|
US7745436B2
(en)
|
2004-04-13 |
2010-06-29 |
Synta Pharmaceuticals Corporation |
Disalt inhibitors of IL-12 production
|
NZ550320A
(en)
|
2004-04-15 |
2010-02-26 |
Chiasma Inc |
Compositions capable of facilitating penetration across a biological barrier
|
ES2246694B1
(es)
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
EP1755680A1
(en)
|
2004-05-03 |
2007-02-28 |
Novartis AG |
Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
|
US20100226931A1
(en)
|
2004-06-24 |
2010-09-09 |
Nicholas Valiante |
Compounds for immunopotentiation
|
US7534448B2
(en)
|
2004-07-01 |
2009-05-19 |
Yale University |
Methods of treatment with drug loaded polymeric materials
|
CA2573103A1
(en)
|
2004-07-06 |
2006-02-09 |
Angion Biomedica Corporation |
Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
|
EP2364699A1
(en)
|
2004-09-13 |
2011-09-14 |
Eisai R&D Management Co., Ltd. |
Joint use of sulfonamide based compound with angiogenesis inhibitor
|
WO2006031848A2
(en)
|
2004-09-15 |
2006-03-23 |
Ivax Corporation |
Corticosteroid topical dispersion with low content of surfactant
|
BRPI0516024A
(pt)
*
|
2004-09-27 |
2008-08-19 |
Astrazeneca Ab |
uso de azd 2171 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
|
AU2005292145C1
(en)
|
2004-10-01 |
2011-07-21 |
Ramscor, Inc. |
Conveniently implantable sustained release drug compositions
|
US20070054916A1
(en)
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
TW200616612A
(en)
|
2004-10-08 |
2006-06-01 |
Wyeth Corp |
Method for the teatment of polycystic kidney disease field of invention
|
WO2006040526A1
(en)
*
|
2004-10-12 |
2006-04-20 |
Astrazeneca Ab |
Quinazoline derivatives for use against cancer
|
WO2006044660A2
(en)
|
2004-10-14 |
2006-04-27 |
Vanderbilt University |
Functionalized solid lipid nanoparticles and methods of making and using same
|
EP1827434B1
(en)
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
CA2590098C
(en)
|
2004-12-10 |
2015-03-31 |
Justin Hanes |
Functionalized poly (ether-anhydride) block copolymers
|
CA2598448A1
(en)
|
2005-02-18 |
2006-08-24 |
Novartis Vaccines And Diagnostics, Inc. |
Antiangiogenic agents with aldesleukin
|
DE102005009705A1
(de)
|
2005-03-03 |
2006-09-07 |
Universität des Saarlandes |
Selektive Hemmstoffe humaner Corticoidsynthasen
|
US9271963B2
(en)
|
2005-03-03 |
2016-03-01 |
Universitat Des Saarlandes |
Selective inhibitors of human corticosteroid synthases
|
DE102005011786A1
(de)
|
2005-03-11 |
2006-09-14 |
Pharmasol Gmbh |
Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
|
US8048889B2
(en)
|
2005-03-29 |
2011-11-01 |
Xtl Biopharmaceuticals Ltd. |
3,4-disubstituted coumarin and quinolone compounds
|
AU2006228683B2
(en)
|
2005-04-01 |
2012-02-02 |
Vfp Therapies |
New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-Alzheimer agents
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
GB0509227D0
(en)
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Intracellular enzyme inhibitors
|
GB0509224D0
(en)
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Inhibitors of intracellular enzymatic activity
|
ZA200709251B
(en)
|
2005-05-10 |
2009-08-26 |
Alcon Inc |
Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
|
MX2007014261A
(es)
|
2005-05-18 |
2008-01-22 |
Wyeth Corp |
Inhibidores de 3-cianoquinolina de cinasa tpl2 y metodos de elaboracion y uso de los mismos.
|
CN101180269A
(zh)
|
2005-05-25 |
2008-05-14 |
惠氏公司 |
制备3-氰基-喹啉的方法和由其制得的中间体
|
WO2006127207A1
(en)
|
2005-05-25 |
2006-11-30 |
Wyeth |
Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
|
CN1313449C
(zh)
|
2005-07-14 |
2007-05-02 |
沈阳中海生物技术开发有限公司 |
新的喹唑啉类衍生物、含有其的药物组合物以及它们的用途
|
US20100105031A1
(en)
|
2005-08-01 |
2010-04-29 |
Esai R & D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
US9006240B2
(en)
|
2005-08-02 |
2015-04-14 |
Eisai R&D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
FR2889527A1
(fr)
|
2005-08-05 |
2007-02-09 |
Servier Lab |
Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
JP4792262B2
(ja)
|
2005-09-09 |
2011-10-12 |
富士フイルム株式会社 |
有機電界発光素子及び錯体化合物
|
US7732613B2
(en)
|
2005-09-14 |
2010-06-08 |
Bristol-Myers Squibb Company |
Met kinase inhibitors
|
AU2006293410B2
(en)
|
2005-09-20 |
2012-10-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd |
Nanoparticles for targeted delivery of active agents
|
US7875602B2
(en)
|
2005-10-21 |
2011-01-25 |
Sutter West Bay Hospitals |
Camptothecin derivatives as chemoradiosensitizing agents
|
CN1955183B
(zh)
|
2005-10-28 |
2011-04-20 |
中国医学科学院药物研究所 |
20-位酯化的喜树碱衍生物、其制法和其药物组合物与用途
|
EP1785420A1
(en)
|
2005-11-14 |
2007-05-16 |
4Sc Ag |
Thiazole analogues and uses thereof
|
US20070149523A1
(en)
|
2005-11-14 |
2007-06-28 |
Jan Ehlert |
Thiazole Analogues and Uses Thereof
|
KR20080089344A
(ko)
|
2005-12-14 |
2008-10-06 |
에프. 호프만-라 로슈 아게 |
C형 간염 바이러스(hcv) 전구약물 제형
|
WO2007076448A2
(en)
|
2005-12-23 |
2007-07-05 |
Alcon, Inc. |
Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
|
US20080058312A1
(en)
|
2006-01-11 |
2008-03-06 |
Angion Biomedica Corporation |
Modulators of hepatocyte growth factor/c-Met activity
|
US20070196860A1
(en)
|
2006-01-18 |
2007-08-23 |
Invitrogen Corporation |
Methods for Measuring Real Time Kinase Activity
|
US20070178051A1
(en)
|
2006-01-27 |
2007-08-02 |
Elan Pharma International, Ltd. |
Sterilized nanoparticulate glucocorticosteroid formulations
|
US8021839B2
(en)
|
2006-02-24 |
2011-09-20 |
Investigen, Inc. |
Methods and compositions for detecting polynucleotides
|
GB2444101A
(en)
|
2006-02-24 |
2008-05-28 |
Investigen Inc |
Methods and compositions for detecting polynucleotides
|
WO2007104696A1
(en)
|
2006-03-15 |
2007-09-20 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Antimalarial agents having polyaromatic structure
|
GB0605691D0
(en)
|
2006-03-21 |
2006-05-03 |
Novartis Ag |
Organic Compounds
|
AU2007232206B2
(en)
|
2006-03-30 |
2013-04-04 |
Drais Pharmaceuticals, Inc. |
Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
|
KR20080112380A
(ko)
|
2006-04-14 |
2008-12-24 |
아스트라제네카 아베 |
Csf-1r 키나제 억제제로서의 4-아닐리노퀴놀린-3-카르복스아미드
|
EP2024342A2
(en)
|
2006-05-01 |
2009-02-18 |
Pfizer Products Incorporated |
Substituted 2-amino-fused heterocyclic compounds
|
US20100003291A1
(en)
|
2006-05-15 |
2010-01-07 |
Liquidia Technologies, Inc. |
Nano-particles for cosmetic applications
|
CA2694955A1
(en)
|
2006-05-15 |
2007-11-22 |
Presidio Pharmaceuticals, Inc. |
3,4-disubstituted coumarin and quinolone compounds
|
US7691811B2
(en)
|
2006-05-25 |
2010-04-06 |
Bodor Nicholas S |
Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
|
EP2032538A2
(en)
|
2006-06-08 |
2009-03-11 |
Array Biopharma, Inc. |
Quinoline compounds and methods of use
|
WO2008001956A1
(fr)
|
2006-06-29 |
2008-01-03 |
Eisai R & D Management Co., Ltd. |
Agent thérapeutique contre la fibrose hépatique
|
KR20090109527A
(ko)
|
2006-07-07 |
2009-10-20 |
칼립시스, 인코포레이티드 |
Pde4의 바이사이클릭 헤테로아릴 억제제
|
WO2008020302A2
(en)
|
2006-08-17 |
2008-02-21 |
Pfizer Products Inc. |
Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
|
ATE498393T1
(de)
|
2006-09-08 |
2011-03-15 |
Univ Johns Hopkins |
Zusammensetzungen zur transportintensivierung durch die schleimhaut
|
CA2662587C
(en)
|
2006-09-11 |
2013-08-06 |
Curis, Inc. |
Quinazoline based egfr inhibitors
|
WO2008033924A2
(en)
|
2006-09-12 |
2008-03-20 |
Board Of Regents Of The University Of Nebraska |
Methods and compositions for targeted delivery of therapeutic agents
|
US20080096193A1
(en)
|
2006-10-24 |
2008-04-24 |
Charles Robert Bupp |
Methods and compositions for detecting polynucleotides
|
CL2007003158A1
(es)
|
2006-11-02 |
2008-05-16 |
Astrazeneca Ab |
Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
|
TW200829555A
(en)
|
2006-11-10 |
2008-07-16 |
Astrazeneca Ab |
Chemical compounds
|
US20080175887A1
(en)
|
2006-11-20 |
2008-07-24 |
Lixiao Wang |
Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
|
EP2125780B1
(en)
|
2006-12-20 |
2012-08-29 |
Amgen Inc. |
Substituted heterocycles and methods of use
|
CN100540552C
(zh)
|
2007-02-01 |
2009-09-16 |
中国药科大学 |
3-氰基喹啉衍生物、其制备方法及其医药用途
|
CN100540551C
(zh)
|
2007-02-01 |
2009-09-16 |
中国药科大学 |
喹啉衍生物、其制备方法及其医药用途
|
WO2008097976A1
(en)
|
2007-02-09 |
2008-08-14 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
WO2008103277A2
(en)
|
2007-02-16 |
2008-08-28 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
|
JP2008214323A
(ja)
|
2007-03-08 |
2008-09-18 |
Kyowa Hakko Kogyo Co Ltd |
皮膚疾患の治療及び/または予防剤
|
CN101679308B
(zh)
|
2007-03-14 |
2014-05-07 |
埃克塞里艾克西斯公司 |
Hedgehog途径抑制剂
|
WO2008113161A1
(en)
|
2007-03-19 |
2008-09-25 |
Ulysses Pharmaceutical Products Inc. |
Phosphate prodrugs of quinazolinyl nitrofurans, methods of obtaining, and use of same
|
DE102007015169A1
(de)
|
2007-03-27 |
2008-10-02 |
Universität des Saarlandes Campus Saarbrücken |
17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
|
JP2010523595A
(ja)
|
2007-04-04 |
2010-07-15 |
マサチューセッツ インスティテュート オブ テクノロジー |
ポリ(アミノ酸)ターゲッティング部分
|
DE102007017654A1
(de)
|
2007-04-12 |
2008-10-16 |
Henkel Ag & Co. Kgaa |
Bis(hydroxychinolin)-Metallkomplexe als Bleichkatalysatoren
|
CN101317847B
(zh)
|
2007-06-06 |
2010-10-13 |
深圳市瑞谷医药技术有限公司 |
一种眼用或耳鼻用药物组合物及其用途
|
US7928111B2
(en)
|
2007-06-08 |
2011-04-19 |
Senomyx, Inc. |
Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
|
TW200904817A
(en)
|
2007-06-19 |
2009-02-01 |
Astrazeneca Ab |
Compounds and uses thereof
|
WO2009014730A1
(en)
|
2007-07-26 |
2009-01-29 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
EP2182799A4
(en)
|
2007-07-27 |
2015-01-21 |
Univ Leland Stanford Junior |
SUPRAMOLECULAR FUNCTIONALIZATION OF GRAPHIC NANOPARTICLES FOR DRUG DELIVERY
|
CN101108846B
(zh)
|
2007-08-10 |
2011-02-09 |
东南大学 |
4-芳香氨基喹唑啉衍生物及制备方法和在制药中的应用
|
US20090062337A1
(en)
|
2007-08-31 |
2009-03-05 |
Wysis Technology Foundation, Inc. |
Treatment of Microbial Infections
|
WO2009030224A2
(de)
|
2007-09-07 |
2009-03-12 |
Schebo Biotech Ag |
Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
|
DE102008012435A1
(de)
*
|
2008-02-29 |
2009-09-03 |
Schebo Biotech Ag |
Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie
|
TW200922590A
(en)
*
|
2007-09-10 |
2009-06-01 |
Curis Inc |
VEGFR inhibitors containing a zinc binding moiety
|
US20110306572A1
(en)
|
2007-09-24 |
2011-12-15 |
Tragara Pharmaceuticals, Inc |
COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]
|
ES2385118T3
(es)
|
2008-01-17 |
2012-07-18 |
Bayer Pharma Aktiengesellschaft |
Derivados de quinazolina sustituida con sulfoximina como inmunomoduladores, su preparación y uso como medicamentos
|
WO2009094211A1
(en)
|
2008-01-22 |
2009-07-30 |
Concert Pharmaceuticals Inc. |
Quinazoline compounds and methods of treating cancer
|
US8133695B2
(en)
|
2008-02-28 |
2012-03-13 |
Life Technologies Corporation |
Fluorescence polarization hERG assay
|
WO2009126691A1
(en)
|
2008-04-09 |
2009-10-15 |
Infinity Pharmaceuticals, Inc |
Inhibitors of fatty acid amide hydrolase
|
WO2009140549A1
(en)
|
2008-05-14 |
2009-11-19 |
Amgen Inc. |
Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
|
EP2149565A1
(de)
|
2008-07-24 |
2010-02-03 |
Bayer Schering Pharma AG |
Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
|
US8211911B2
(en)
|
2008-08-19 |
2012-07-03 |
Guoqing Paul Chen |
Compounds as kinase inhibitors
|
TWI580441B
(zh)
|
2008-09-19 |
2017-05-01 |
愛爾康研究有限公司 |
穩定的藥學次微米懸浮液及其形成方法
|
AU2009303602B2
(en)
*
|
2008-10-14 |
2012-06-14 |
Sunshine Lake Pharma Co., Ltd. |
Compounds and methods of use
|
WO2010056758A1
(en)
|
2008-11-12 |
2010-05-20 |
Yangbo Feng |
Quinazoline derivatives as kinase inhibitors
|
CN101747306B
(zh)
|
2008-11-28 |
2012-08-29 |
中国中化股份有限公司 |
取代醚类化合物及其应用
|
JP5471063B2
(ja)
|
2009-02-23 |
2014-04-16 |
住友化学株式会社 |
環状化合物、その金属錯体及び変性金属錯体
|
TWI461197B
(zh)
|
2009-03-12 |
2014-11-21 |
|
2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
|
CA2755251A1
(en)
|
2009-03-18 |
2010-09-23 |
Schering Corporation |
Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
|
US10952965B2
(en)
|
2009-05-15 |
2021-03-23 |
Baxter International Inc. |
Compositions and methods for drug delivery
|
WO2010151784A2
(en)
|
2009-06-26 |
2010-12-29 |
The General Hospital Corporation |
Antimicrobial compounds
|
EP2496234A1
(en)
|
2009-11-07 |
2012-09-12 |
Merck Patent GmbH |
Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
|
EP2335686A1
(en)
|
2009-12-21 |
2011-06-22 |
LEK Pharmaceuticals d.d. |
An aqueous intravenous nanosuspension with reduced adverse effects
|
DE102010006121B4
(de)
|
2010-01-29 |
2022-08-11 |
Merck Patent Gmbh |
Materialien für organische Elektrolumineszenzvorrichtungen
|
DE102010007938A1
(de)
|
2010-02-12 |
2011-10-06 |
Merck Patent Gmbh |
Elektrolumineszierende Polymere, Verfahren zu ihrer Herstellung sowie ihre Verwendung
|
WO2011106168A1
(en)
|
2010-02-24 |
2011-09-01 |
Dcam Pharma Inc |
Purine compounds for treating autoimmune and demyelinating diseases
|
WO2011106702A2
(en)
|
2010-02-25 |
2011-09-01 |
The Johns Hopkins University |
Sustained delivery of therapeutic agents to an eye compartment
|
JP5654246B2
(ja)
|
2010-03-03 |
2015-01-14 |
一般社団法人ファルマバレープロジェクト支援機構 |
キナゾリン化合物を有効成分とする医薬組成物
|
TWI516264B
(zh)
|
2010-05-06 |
2016-01-11 |
臺北醫學大學 |
芳香醯喹啉化合物
|
DE102010023949A1
(de)
|
2010-06-16 |
2011-12-22 |
F. Holzer Gmbh |
In-situ Lecithin-Mikroemulsionsgel-Formulierung
|
WO2011159328A1
(en)
|
2010-06-16 |
2011-12-22 |
Dynavax Technologies Corporation |
Methods of treatment using tlr7 and/or tlr9 inhibitors
|
US20120252756A1
(en)
|
2010-06-25 |
2012-10-04 |
Coffey Martin J |
Pharmaceutical Compositions and Methods for Treating, Controlling, Ameliorating, or Reversing Conditions of the Eye
|
CA2803890A1
(en)
|
2010-06-25 |
2011-12-29 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
EP2585461B1
(en)
|
2010-06-28 |
2020-02-26 |
Merck Patent GmbH |
2,4-diaryl-substituted [1,8]naphthyridines as kinase inhibitors for use against cancer
|
EP2595613B1
(en)
|
2010-07-22 |
2019-01-09 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Compounds for use in a method of preventing or treating viral infection
|
EP2598131A1
(fr)
|
2010-07-29 |
2013-06-05 |
Laboratoires Fournier S.A. |
Composes pour le traitement/la prevention des maladies inflammatoires oculaires
|
CA2807097A1
(en)
|
2010-07-30 |
2012-02-02 |
Ranbaxy Laboratories Limited |
Matrix metalloproteinase inhibitors
|
EP2609084A1
(en)
|
2010-08-27 |
2013-07-03 |
Grünenthal GmbH |
Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
|
WO2012039979A2
(en)
|
2010-09-10 |
2012-03-29 |
The Johns Hopkins University |
Rapid diffusion of large polymeric nanoparticles in the mammalian brain
|
WO2012040499A2
(en)
|
2010-09-22 |
2012-03-29 |
Surface Logix, Inc. |
Metabolic inhibitors
|
BR112013008008A2
(pt)
|
2010-09-24 |
2016-06-21 |
Ranbaxy Lab Ltd |
composto, composição farmacêutica e processo para preparar um composto
|
MX2013003364A
(es)
|
2010-09-24 |
2013-06-05 |
Ranbaxy Lab Ltd |
Inhibidores de metaloproteinasa de matriz.
|
KR20130137174A
(ko)
|
2010-09-24 |
2013-12-16 |
랜박시 래보러터리스 리미티드 |
기질 메탈로프로테나제 저해제
|
US9597325B2
(en)
|
2010-10-13 |
2017-03-21 |
Trustees Of Boston University |
Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
|
JP2013543844A
(ja)
|
2010-10-22 |
2013-12-09 |
バインド セラピューティックス インコーポレイテッド |
高分子コポリマーを含む治療用ナノ粒子
|
EP2635254B1
(en)
|
2010-11-05 |
2019-05-15 |
The John Hopkins University |
Compositions and methods relating to reduced mucoadhesion
|
DE102010050570A1
(de)
|
2010-11-05 |
2012-05-10 |
F. Holzer Gmbh |
Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors
|
WO2012064897A2
(en)
|
2010-11-09 |
2012-05-18 |
Yuan Chen |
Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use
|
WO2012071042A1
(en)
|
2010-11-24 |
2012-05-31 |
Government Of The U.S.A. Represented By The Secretary, Dept. Of Health & Human Services |
Compositions and methods for treating or preventing lupus
|
WO2012074980A2
(en)
|
2010-12-01 |
2012-06-07 |
Dara Biosciences, Inc. |
Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives
|
AR084433A1
(es)
|
2010-12-22 |
2013-05-15 |
Ironwood Pharmaceuticals Inc |
Inhibidores de la faah y composiciones farmaceuticas que los contienen
|
WO2012088431A1
(en)
|
2010-12-23 |
2012-06-28 |
Ironwood Pharmaceuticals, Inc. |
Faah inhibitors
|
EP2661269A1
(en)
|
2011-01-03 |
2013-11-13 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
|
CN103313992B
(zh)
|
2011-01-12 |
2016-04-27 |
天堃医药科技(杭州)有限公司 |
具有hdac抑制作用的喜树碱衍生物
|
WO2012106534A2
(en)
|
2011-02-02 |
2012-08-09 |
The Regents Of The University Of California |
Hiv integrase inhibitors
|
US9327037B2
(en)
|
2011-02-08 |
2016-05-03 |
The Johns Hopkins University |
Mucus penetrating gene carriers
|
US20120214803A1
(en)
|
2011-02-18 |
2012-08-23 |
Vifor (International) Ag |
Novel Sulfonaminoquinoline Hepcidin Antagonists
|
EP2678052B1
(en)
|
2011-02-24 |
2018-09-26 |
Emory University |
Jab1 blocking compositions for ossification and methods related thereto
|
WO2012127506A1
(en)
|
2011-03-22 |
2012-09-27 |
Advinus Therapeutics Limited |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
WO2012135416A1
(en)
|
2011-03-29 |
2012-10-04 |
Trana Discovery, Inc. |
Screening methods for identifying specific staphylococcus aureus inhibitors
|
CA2833305A1
(en)
|
2011-04-14 |
2012-10-18 |
Allergan, Inc. |
Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
|
US8507686B2
(en)
|
2011-04-14 |
2013-08-13 |
Allergan, Inc. |
Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
|
MX2013012211A
(es)
|
2011-04-18 |
2013-12-09 |
Allergan Inc |
Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato.
|
JP6211513B2
(ja)
|
2011-04-26 |
2017-10-11 |
ジェネンテック, インコーポレイテッド |
自己免疫疾患の治療のための組成物及び方法
|
US8835410B2
(en)
|
2011-05-10 |
2014-09-16 |
Bodor Laboratories, Inc. |
Treatment of eyelid dermatitis
|
MX360666B
(es)
|
2011-05-12 |
2018-11-13 |
Foresight Biotherapeutics Inc |
Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides.
|
US20140235548A1
(en)
|
2011-05-17 |
2014-08-21 |
Cleave Biosciences, Inc. |
Compositions and methods for jamm protein inhibition
|
US9439884B2
(en)
|
2011-05-26 |
2016-09-13 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for the treatment of immune disorders
|
AR086798A1
(es)
|
2011-06-29 |
2014-01-22 |
Otsuka Pharma Co Ltd |
Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen
|
WO2013013614A1
(zh)
|
2011-07-28 |
2013-01-31 |
南京英派药业有限公司 |
4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
|
JP5753027B2
(ja)
|
2011-08-22 |
2015-07-22 |
ユー・ディー・シー アイルランド リミテッド |
有機電界発光素子、化合物、並びに該素子を用いた発光装置、表示装置及び照明装置
|
TW201808311A
(zh)
|
2011-09-16 |
2018-03-16 |
遠景生物製藥股份有限公司 |
安定之普維酮-碘組成物
|
WO2013061269A1
(en)
|
2011-10-26 |
2013-05-02 |
Micro Labs Limited |
Combinations of loteprednol and olopatadine for the treatment of ocular allergies
|
WO2013067449A1
(en)
|
2011-11-03 |
2013-05-10 |
Taiwan Liposome Company, Ltd. |
Pharmaceutical compositions of hydrophobic camptothecin derivatives
|
WO2013065028A1
(en)
|
2011-11-04 |
2013-05-10 |
Micro Labs Limited |
Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections
|
US20130116279A1
(en)
|
2011-11-07 |
2013-05-09 |
Kalypsys, Inc. |
Bicyclic heteroaryl inhibitors of pde4
|
WO2013070852A2
(en)
|
2011-11-08 |
2013-05-16 |
Emory University |
Compounds and compositions used to epigenetically transform cells and methods related thereto
|
CN103102342B
(zh)
|
2011-11-14 |
2014-10-29 |
广东东阳光药业有限公司 |
氨基喹唑啉类衍生物及其盐和使用方法
|
TWI577671B
(zh)
|
2011-11-14 |
2017-04-11 |
Sunshine Lake Pharma Co Ltd |
Aminoquinazoline derivatives and salts thereof and methods of use thereof
|
CN103102345B
(zh)
|
2011-11-14 |
2015-06-03 |
广东东阳光药业有限公司 |
氨基喹唑啉类衍生物及其盐和使用方法
|
US9328138B2
(en)
|
2011-11-15 |
2016-05-03 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
CA2859046C
(en)
|
2011-12-14 |
2019-10-22 |
The Johns Hopkins University |
Nanoparticles with enhanced mucosal penetration or decreased inflammation
|
CN103183674B
(zh)
|
2011-12-31 |
2017-09-12 |
江苏先声药业有限公司 |
一类稠杂环衍生物及其应用
|
WO2013118071A1
(en)
|
2012-02-09 |
2013-08-15 |
Glenmark Pharmaceuticals S.A. |
BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
|
EP2812296A1
(en)
|
2012-02-10 |
2014-12-17 |
The Regents of The University of California |
First row metal-based catalysts for hydosilylation
|
CN103304572A
(zh)
|
2012-03-09 |
2013-09-18 |
上海医药集团股份有限公司 |
一类3-氰基喹啉类化合物及其药用组合物和应用
|
WO2013158928A2
(en)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
US9056057B2
(en)
|
2012-05-03 |
2015-06-16 |
Kala Pharmaceuticals, Inc. |
Nanocrystals, compositions, and methods that aid particle transport in mucus
|
WO2013166436A1
(en)
|
2012-05-03 |
2013-11-07 |
Kala Pharmaceuticals, Inc. |
Pharmaceutical nanoparticles showing improved mucosal transport
|
EP2844227B1
(en)
|
2012-05-03 |
2020-11-18 |
Kala Pharmaceuticals, Inc. |
Pharmaceutical nanoparticles showing improved mucosal transport
|
EP2854818A4
(en)
|
2012-06-01 |
2016-04-06 |
Oxalys Pharmaceuticals |
CHEMICAL SUPPRESSORS OF NEUROTOXICITY IN SYNUCLEOPOPHISTIC DISEASES
|
CN104583206A
(zh)
|
2012-06-15 |
2015-04-29 |
加利福尼亚大学董事会 |
用于脑癌的新颖治疗剂
|
EA030687B1
(ru)
|
2012-07-20 |
2018-09-28 |
Клив Байосайенсиз, Инк. |
КОНДЕНСИРОВАННЫЕ ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КОМПЛЕКСА p97
|
CN103804292A
(zh)
|
2012-11-05 |
2014-05-21 |
江苏唐果医药科技有限公司 |
Hdm2和hdmx双重抑制剂3-腈基喹啉衍生物及其制备方法与应用
|
WO2014074517A1
(en)
|
2012-11-08 |
2014-05-15 |
Emory University |
Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
|
MX2015005841A
(es)
|
2012-11-08 |
2016-01-08 |
Agios Pharmaceuticals Inc |
Compuestos y composiciones terapeuticos y su uso como moduladores pkm2.
|
US9701638B2
(en)
|
2012-11-09 |
2017-07-11 |
Rutgers, The State University Of New Jersey |
Therapeutic hydroxyquinolones
|
KR102051910B1
(ko)
|
2012-11-30 |
2019-12-09 |
에스에프씨주식회사 |
중수소 치환된 유기금속 착물 및 이를 포함하는 유기 발광 소자
|
WO2014086284A1
(zh)
|
2012-12-04 |
2014-06-12 |
上海医药集团股份有限公司 |
一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
|
JP6556630B2
(ja)
|
2012-12-21 |
2019-08-07 |
メルク パテント ゲーエムベーハー |
金属錯体
|
KR102084421B1
(ko)
|
2013-02-15 |
2020-03-05 |
에스에프씨주식회사 |
신규한 유기 화합물 및 이를 포함하는 유기 발광 소자
|
CN107915751A
(zh)
|
2013-02-20 |
2018-04-17 |
卡拉制药公司 |
治疗性化合物和其用途
|
KR102118013B1
(ko)
|
2013-02-22 |
2020-06-05 |
에스에프씨주식회사 |
신규한 유기 화합물 및 이를 포함하는 유기 발광 소자
|
KR20150123908A
(ko)
|
2013-03-04 |
2015-11-04 |
어드밴스드 메디컬 리서치 인스티튜트 오브 캐나다 |
퀴놀린 술포닐 유도체 및 그의 용도
|
WO2014141057A2
(en)
|
2013-03-12 |
2014-09-18 |
Mahesh Kandula |
Compositions and methods for the treatment of cancer
|
EP2968360B1
(en)
|
2013-03-14 |
2021-01-20 |
ConverGene LLC |
Quinolinone derivatives for the inhibition of bromodomain-containing proteins
|
WO2014141110A2
(en)
|
2013-03-14 |
2014-09-18 |
Curadev Pharma Pvt. Ltd. |
Aminonitriles as kynurenine pathway inhibitors
|
CA2902734A1
(en)
|
2013-03-18 |
2014-09-25 |
Genoscience Pharma |
Quinolines derivatives as novel anticancer agents
|
US9394254B2
(en)
|
2013-05-08 |
2016-07-19 |
The University of Denver and Regis University |
Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase
|
CA2912064A1
(en)
|
2013-05-16 |
2014-11-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds for inhibiting drug-resistant strains of hiv-1 integrase
|
JP6419802B2
(ja)
|
2013-10-14 |
2018-11-07 |
メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングMerck Patent GmbH |
電子素子のための材料
|
MX355330B
(es)
|
2013-11-01 |
2018-04-16 |
Kala Pharmaceuticals Inc |
Formas cristalinas de compuestos terapeuticos y sus usos.
|